Fundraising Fox
IntelliCyt
Acquired10,112 employees on LinkedIn · 2 known investors
Find your way into IntelliCyt
Sign up to see every warm intro you have to IntelliCyt
- Paths you didn't know you had: your email and LinkedIn already hold routes to the IntelliCyt team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Intellicyt (now part of Sartorius) develops the iQue high-throughput screening (HTS) flow cytometry platform, which combines sampling hardware and analysis software to generate multiplexed cell phenotype and function data from 96- or 384-well plates. It serves life science researchers working in areas such as antibody discovery, T-cell engineering, and immuno-oncology.
Investors · 2
Frequently asked questions
- What does IntelliCyt do?
- Intellicyt (now part of Sartorius) develops the iQue high-throughput screening (HTS) flow cytometry platform, which combines sampling hardware and analysis software to generate multiplexed cell phenotype and function data from 96- or 384-well plates. It serves life science researchers working in areas such as antibody discovery, T-cell engineering, and immuno-oncology.
- Who are IntelliCyt's investors?
- IntelliCyt's investors include Arboretum Ventures, Saba Investments.